Sartorius Stedim Biotech (DIM) Stock Overview
Engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 4/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
DIM Community Fair Values
Create NarrativeSee what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Sartorius Stedim Biotech S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €176.50 |
| 52 Week High | €224.00 |
| 52 Week Low | €150.00 |
| Beta | 1.09 |
| 1 Month Change | 13.50% |
| 3 Month Change | 3.73% |
| 1 Year Change | -8.88% |
| 3 Year Change | -34.48% |
| 5 Year Change | -51.68% |
| Change since IPO | 2,047.64% |
Recent News & Updates
Recent updates
Earnings Miss: Sartorius Stedim Biotech S.A. Missed EPS By 7.2% And Analysts Are Revising Their Forecasts
It's been a sad week for Sartorius Stedim Biotech S.A. ( EPA:DIM ), who've watched their investment drop 14% to €162 in...A Look At The Fair Value Of Sartorius Stedim Biotech S.A. (EPA:DIM)
Key Insights Sartorius Stedim Biotech's estimated fair value is €191 based on 2 Stage Free Cash Flow to Equity With...
DIM: Bioprocessing Recovery Expectations Will Drive Constructive Outlook Despite Recent Downgrades
Narrative Update: Sartorius Stedim Biotech The analyst fair value estimate for Sartorius Stedim Biotech has edged from about €241 to €240 as analysts factor in recent downgrades that point to the bioprocessing recovery and recent share outperformance already being reflected in the current price. Analyst Commentary Recent research updates around Sartorius Stedim Biotech are clustered around the view that the current share price already captures a meaningful part of the expected recovery in bioprocessing.What Is Sartorius Stedim Biotech S.A.'s (EPA:DIM) Share Price Doing?
Sartorius Stedim Biotech S.A. ( EPA:DIM ) saw significant share price movement during recent months on the ENXTPA...DIM: Bioprocessing Recovery Expectations Will Shape Constructive Outlook Despite Rating Downgrades
Analysts have trimmed their fair value estimate for Sartorius Stedim Biotech by a fraction to about €241, reflecting a mix of more cautious ratings after recent share outperformance and recovery expectations in bioprocessing that are now seen as better reflected in the price, even as some targets, such as the €250 level, have edged higher. Analyst Commentary Recent research paints a mixed picture for Sartorius Stedim Biotech, with price targets clustering in the €240 to €250 range and ratings moving toward more neutral stances after the share price recovery.Why We're Not Concerned About Sartorius Stedim Biotech S.A.'s (EPA:DIM) Share Price
Sartorius Stedim Biotech S.A.'s ( EPA:DIM ) price-to-earnings (or "P/E") ratio of 79.2x might make it look like a...DIM: Raised 2025 Guidance And Updated Assumptions Will Shape Balanced Outlook
Analysts have nudged their price expectations for Sartorius Stedim Biotech higher, with one recent move lifting a target to €250 from €230. This change reflects updated assumptions around discount rates, growth and P/E inputs.DIM: Raised 2025 Guidance Will Support Stronger Prospects Ahead
Analysts have modestly raised their price target for Sartorius Stedim Biotech to approximately €241 from about €237, citing a slightly higher assumed future valuation multiple that more than offsets marginally lower growth and profitability expectations. What's in the News Sartorius Stedim Biotech raised its 2025 sales revenue growth guidance to around 9 percent, up from a prior forecast of 7 percent plus or minus 2 percentage points.Here's Why Sartorius Stedim Biotech (EPA:DIM) Can Manage Its Debt Responsibly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...DIM: Higher Future Multiple Will Support Stronger Prospects Ahead
Analysts have raised their price target for Sartorius Stedim Biotech by approximately €5 to around €237, citing slightly improved profit margin expectations and a willingness to apply a higher future price-to-earnings multiple, despite modestly softer revenue growth forecasts. What's in the News Sartorius Stedim Biotech raised its 2025 sales revenue growth guidance to around 9 percent, up from the prior forecast of 7 percent with a plus/minus 2 percentage point range (company guidance).High Consumable Demand And Regulatory Standards Will Drive Future Success
Analysts have modestly raised their price target for Sartorius Stedim Biotech from €229.62 to €231.92. They cited improved revenue growth and higher profit margin projections as key drivers for the adjustment.Is Sartorius Stedim Biotech S.A. (EPA:DIM) Potentially Undervalued?
Sartorius Stedim Biotech S.A. ( EPA:DIM ) led the ENXTPA gainers with a relatively large price hike in the past couple...High Consumable Demand And Regulatory Standards Will Drive Future Success
Analysts have slightly lowered their price target for Sartorius Stedim Biotech from €233.31 to €229.62, citing minor adjustments in discount rates and projected revenue growth. What's in the News Sartorius Stedim Biotech and Bio Usawa Biotechnology announced a strategic partnership to accelerate Africa's biopharmaceutical industry.Is There An Opportunity With Sartorius Stedim Biotech S.A.'s (EPA:DIM) 21% Undervaluation?
Key Insights The projected fair value for Sartorius Stedim Biotech is €221 based on 2 Stage Free Cash Flow to Equity...Is There Now An Opportunity In Sartorius Stedim Biotech S.A. (EPA:DIM)?
Sartorius Stedim Biotech S.A. ( EPA:DIM ) saw a significant share price rise of 27% in the past couple of months on the...Is Sartorius Stedim Biotech (EPA:DIM) A Risky Investment?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Increased Order Intake And Efficiency Drive Future Growth Amidst Global Challenges
Increased order intake for consumables indicates future recurring revenue stability as customer destocking improves, highlighting positive growth trends.Shareholder Returns
| DIM | FR Life Sciences | FR Market | |
|---|---|---|---|
| 7D | 3.1% | -1.1% | -1.4% |
| 1Y | -8.9% | -6.6% | 0.3% |
Return vs Industry: DIM underperformed the French Life Sciences industry which returned -5.5% over the past year.
Return vs Market: DIM underperformed the French Market which returned 1.8% over the past year.
Price Volatility
| DIM volatility | |
|---|---|
| DIM Average Weekly Movement | 6.9% |
| Life Sciences Industry Average Movement | 7.2% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in FR Market | 11.2% |
| 10% least volatile stocks in FR Market | 2.8% |
Stable Share Price: DIM has not had significant price volatility in the past 3 months compared to the French market.
Volatility Over Time: DIM's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1978 | 10,456 | Rene Faber | www.sartorius.com |
Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; reagents; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides fluid management services; biolayer interferometry instruments; microbiology testing, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; screening instruments; biomolecule analysis tools; batch liquid chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; water purification systems; and weighing products.
Sartorius Stedim Biotech S.A. Fundamentals Summary
| DIM fundamental statistics | |
|---|---|
| Market cap | €17.17b |
| Earnings (TTM) | €268.10m |
| Revenue (TTM) | €2.98b |
Is DIM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DIM income statement (TTM) | |
|---|---|
| Revenue | €2.98b |
| Cost of Revenue | €1.65b |
| Gross Profit | €1.33b |
| Other Expenses | €1.07b |
| Earnings | €268.10m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Jul 23, 2026
| Earnings per share (EPS) | 2.76 |
| Gross Margin | 44.71% |
| Net Profit Margin | 8.98% |
| Debt/Equity Ratio | 58.9% |
How did DIM perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/03 11:47 |
| End of Day Share Price | 2026/06/03 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sartorius Stedim Biotech S.A. is covered by 25 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Charles Pitman | Barclays |
| Nithya Balasubramanian | Bernstein |
| Delphine Le Louet | Bernstein |